Goswami, A., Prasad, A
Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome
Het product is natuurlijk, omdat ze actieve ingredinten van plantaardige en mariene oorsprong bevat, welke zorgvuldig zijn geselecteerd vanwege hun reinigende, vochtafdrijvende en vetregulerende eigenschappen
Recently, the newly developed drug tirzepatide, which targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, was introduced to the market to treat type 2 diabetes and obesity in 2022 and 2023, respectively (Table 1).25,26 GIP (Figure 1G) is another incretin hormone that triggers insulin secretion when a meal is ingested.27 Tirzepatide (Figure 1H) was designed to bind GLP-1/GIP receptors by modifying the native amino acid sequence of GIP.3,28 The combined activation of GLP-1 and GIP receptors more effectively reduces glucose levels and stimulates weight loss compared to the placebo, semaglutide and dulaglutide, or insulin.2931 Table 1
Manufacturing follows controlled production workflows, with internal systems supporting lot level verification of identity and purity